Mannatech (NASDAQ:MTEX – Get Free Report) and Carisma Therapeutics (NASDAQ:CARM – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.
Valuation and Earnings
This table compares Mannatech and Carisma Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mannatech | $108.04 million | 0.07 | -$15.21 million | ($6.71) | -0.61 |
| Carisma Therapeutics | $10.77 million | 0.00 | -$60.48 million | $0.73 | 0.00 |
Analyst Ratings
This is a summary of current ratings and price targets for Mannatech and Carisma Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
| Carisma Therapeutics | 1 | 0 | 1 | 1 | 2.67 |
Carisma Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Mannatech.
Risk and Volatility
Mannatech has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Institutional & Insider Ownership
13.0% of Mannatech shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 41.5% of Mannatech shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Mannatech and Carisma Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mannatech | -11.97% | -2,383.34% | -40.24% |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
Summary
Carisma Therapeutics beats Mannatech on 9 of the 15 factors compared between the two stocks.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
